1614-12-6
1614-12-6 结构式
基本信息
1-氨基苯并三氮唑
1-苯并三唑胺
1-BENZOTRIAZOLAMINE
1H-1,2,3-BENZOTRIAZOL-1-YLAMINE
ABT
RARECHEM AQ NN 0550
TIMTEC-BB SBB004208
1-Benzotriazolylamine
1H-Benzotriazol-1-amine
1H-Benzotriazole,1-amino-
Benzotriazol-1-ylamine
1-Aminobenzotriazole 97%
ABT, 1-Benzotriazoleamine
1-Benzotriazolamine, ABT
1-(Thiophen-2-yl)-4-[(2-aminoethyl)amino]-1-butanone
4-[(2-Aminoethyl)amino]-1-(2-thienyl)butan-1-one
1-Amino-1H-benzotriazole
物理化学性质
安全数据
制备方法
95-14-7
1614-12-6
向苯并三氮唑（5g，42.01mmol）和氢氧化钾（11.76g，0.21mol）的水（50mL）溶液中分批加入羟胺-O-磺酸（9.49g，84.02mmol），同时控制反应温度不超过50℃。加料完毕后，将反应混合物于室温下搅拌2小时。过滤收集沉淀，并用乙酸乙酯充分洗涤。滤液经减压浓缩后，残余物以石油醚：乙酸乙酯（300：1）为洗脱剂，通过硅胶柱色谱法进行纯化，得到1H-苯并[d][1,2,3]三唑-1-胺，为白色固体（1.52g，收率27%）。质谱（ESI）m/z：135 [M + H]+。
参考文献：
[1] Journal of the Chemical Society, Perkin Transactions 1, 2000, # 15, p. 2343 - 2355
[2] Patent: WO2015/100609, 2015, A1. Location in patent: Page/Page column 37
[3] Tetrahedron Letters, 1997, vol. 38, # 28, p. 5037 - 5040
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | 34864 | 1-氨基苯并三唑 1-Aminobenzotriazole, 98%, Thermo Scientific Chemicals | 1614-12-6 | 100mg | 1134元 |
| 2025/05/22 | 34864 | 1-氨基苯并三唑 1-Aminobenzotriazole, 98%, Thermo Scientific Chemicals | 1614-12-6 | 250mg | 2117元 |
| 2025/05/22 | HY-103389 | 1-氨基苯并三唑 1-Aminobenzotriazole | 1614-12-6 | 50mg | 500元 |
常见问题列表
| Target | Value |
|
P450
() | |
|
NAT
() |
1-Aminobenzotriazole (ABT) alone significantly increases the expression levels of CYP2B6 in two different hepatocytes (7.3- and 10.8-fold, respectively). Upon co-treatment with 1-Aminobenzotriazole, the induction of CYP2B6 expression by CITCO or rifampin is potentiated: 12.6- and 4.0-fold for CITCO as well as 3.9- and 2.5-fold for rifampin. 1-Aminobenzotriazole has a greater potentiation effect on CITCO than on rifampin. 1-Aminobenzotriazole alone increases the expression levels of CYP3A4 in tow different hepatocytes (by 2.0- and 3.8-fold). Upon co-treatment with 1-Aminobenzotriazole, the effects of CITCO on CYP3A4 expression levels are potentiated by 3.8- and 6.0- fold as compare to cells treated with CITCO alone. 1-Aminobenzotriazole (ABT) (1 mM) shows pronounced (~95%) inhibition of the formation of N-acetylprocainamide compare with the control without 1-Aminobenzotriazole.
Oral 1-Aminobenzotriazole (ABT) (100 mg/kg, 2 h predose) decreases the clearance of intravenous procainamide (45%) in rats, accompanied by a decreased N-acetylprocainamide-to-procainamide ratio in urine (0.74 versus 0.21) and plasma (area under the curve ratio 0.59 versus 0.11). The urinary recovery of procainamide increases from 18 to 30%, whereas the recovery of N-acetylprocainamide in urine decreases from 13.3 to 6.5% with 1-Aminobenzotriazole. Pretreatment of rats with 100 mg/kg oral 1-Aminobenzotriazole (ABT) administered 2 hours before a semisolid caloric test meal markedly delays gastric emptying. 1-Aminobenzotriazole also increases stomach weights by 2-fold.